A July 17 joint report filed before the U.S. District Court for the District of New Jersey indicates that the number of Benicar lawsuits included in multidistrict litigation (MDL) 2606 now stands at 205. This is a whopping 135 more than the 70 Benicar lawsuits reported at an MDL conference in June, and 190 more than the initial 15 federal cases centralized in March.
Benicar, pharmaceutical giant ...
continue reading...
Philadelphia is known far and wide as a top destination for some of the finest medical care in the country. That position was solidified once more as U.S. News & World Report issued their top hospital rankings for 2015.
The Hospitals of the University of Pennsylvania-Penn Presbyterian was ranked as the top hospital in the Commonwealth and the 9th best hospital in the ...
continue reading...
Patients starting a course of treatment on Cymbalta, Eli Lilly’s former blockbuster antidepressant, were promised the possibility of help. For these patients, their struggle against crippling depression is real. Their symptoms are real. Their hope for a brighter future is real.
Unfortunately, the risks of severe withdrawal symptoms associated with the use of the drug are also very real, according to lawsuits filed against the drug’s manufacturer. Cymbalta patients have ...
continue reading...
Coumadin has been a staple of the medical community for decades. As one of the most popular blood thinners on the market, the drug has been used by millions of patients. Doctors are learning, however, that no two patients react to the drug the same way. In fact, it may be (as one doctor put it) “the most dangerous drug in America.”
Nowhere is this becoming more evident than in ...
continue reading...
In a recent safety communication, the U.S. Food and Drug Administration (FDA) announced it was looking into the potential risk of brain deposits caused by gadolinium-based contrast agents used in magnetic resonance imaging. According to the FDA, repeated exposure to these contrast agents can result in gadolinium deposits in the brain, which may be harmful.
Magnetic resonance imaging (MRI) is a radiological technique used to evaluate the health ...
continue reading...
Nasdaq.com reports that the U.S. Food and Drug Administration (FDA) has approved Praluent, the first of a new and highly anticipated class of cholesterol medications. The drug, jointly developed by Sanofi SA and Regeneron Pharmaceuticals, will provide an alternative to patients who have not had success with statins like Pfizer’s controversial Lipitor.
From 1996 until its patent expired in 2011, Lipitor was the world’s best-selling drug, with an estimated $125 billion in ...
continue reading...
